Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

NCT07683806 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

309

Enrollment

INDUSTRY

Sponsor class

Conditions

Seborrheic Dermatitis

Interventions

DRUG: Roflumilast Foam 0.3%
DRUG: Vehicle foam

Sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Collaborators

[object Object]